Henry Schein Analyst Ratings
Barrington Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $82
Buy Rating Affirmed for Henry Schein Amid Aggressive Share Repurchase and Strategic Growth Initiatives
Henry Schein Analyst Ratings
JPMorgan Adjusts Price Target on Henry Schein to $80 From $88, Maintains Overweight Rating
Henry Schein Analyst Ratings
Henry Schein (HSIC) Faces Sell Rating Amid Slow Recovery and Revised Financial Forecasts
Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Zymeworks (ZYME) and Rocket Pharmaceuticals (RCKT)
Hold Rating on Henry Schein Amidst Revised Guidance and Market Uncertainties
Leerink Partners Maintains Henry Schein(HSIC.US) With Hold Rating
Morgan Stanley Cuts Price Target on Henry Schein to $55 From $60, Underweight Rating Maintained
Henry Schein (HSIC) Receives a Hold From Evercore ISI
Evercore Maintains Henry Schein(HSIC.US) With Hold Rating, Cuts Target Price to $72
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $86
Piper Sandler Reaffirms Their Buy Rating on Henry Schein (HSIC)
Baird Upgrades Henry Schein to Outperform From Neutral, Adjusts Price Target to $92 From $81
Henry Schein Analyst Ratings
Morgan Stanley Adjusts Henry Schein's Price Target to $60 From $65
Henry Schein (HSIC) Gets a Sell From Morgan Stanley
Henry Schein Analyst Ratings